{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:21:53Z","timestamp":1759774913002},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T00:00:00Z","timestamp":1338422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11936-012-0184-7","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T01:26:19Z","timestamp":1338341179000},"page":"356-369","source":"Crossref","is-referenced-by-count":7,"title":["New Issues in Heart Transplantation for Heart Failure"],"prefix":"10.1007","volume":"14","author":[{"given":"Michelle M.","family":"Kittleson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,31]]},"reference":[{"key":"184_CR1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMcp0909392","volume":"362","author":"JJ McMurray","year":"2010","unstructured":"McMurray JJ. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362:228\u201338.","journal-title":"N Engl J Med"},{"key":"184_CR2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Costanzo MR, Dipchand A, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914\u201356. These guidelines are a comprehensive reference and resource on the management of heart transplant recipients.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.healun.2010.08.007","volume":"29","author":"J Stehlik","year":"2010","unstructured":"Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report\u20132010. J Heart Lung Transplant. 2010;29:1089\u2013103.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR4","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.healun.2005.03.019","volume":"24","author":"S Stewart","year":"2005","unstructured":"Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710\u201320.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","volume":"30","author":"J Kobashigawa","year":"2011","unstructured":"Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30:252\u201369. This is a summary of the current state of the art on the diagnosis and treatment of antibody-mediated rejection based on the consensus of experts in the field.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.healun.2009.01.015","volume":"28","author":"GW Wu","year":"2009","unstructured":"Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28:417\u201322.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.healun.2006.08.009","volume":"25","author":"AG Kfoury","year":"2006","unstructured":"Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant. 2006;25:1277\u201382.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-6143.2005.01175.x","volume":"6","author":"MC Deng","year":"2006","unstructured":"Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150\u201360.","journal-title":"Am J Transplant"},{"key":"184_CR9","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1056\/NEJMoa0912965","volume":"362","author":"MX Pham","year":"2010","unstructured":"Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890\u2013900. This was the first trial of the use of the AlloMap gene expression profile to detect rejection in heart transplant recipients.","journal-title":"N Engl J Med"},{"key":"184_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1399-0012.2003.00013.x","volume":"17","author":"R Kowalski","year":"2003","unstructured":"Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77\u201388.","journal-title":"Clin Transplant"},{"key":"184_CR11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/01.tp.0000234837.02126.70","volume":"82","author":"RJ Kowalski","year":"2006","unstructured":"Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation. 2006;82:663\u20138.","journal-title":"Transplantation"},{"key":"184_CR12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.healun.2009.12.015","volume":"29","author":"JA Kobashigawa","year":"2011","unstructured":"Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant. 2011;29:504\u20138. This is one of the largest studies to date in heart transplant recipients examining the utility of the Cylex blood test in the detection of subsequent infection and rejection.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR13","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.transproceed.2011.03.010","volume":"43","author":"F Saraiva","year":"2011","unstructured":"Saraiva F, Matos V, Goncalves L, et al. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant Proc. 2011;43:1908\u201312.","journal-title":"Transplant Proc"},{"key":"184_CR14","first-page":"63","volume":"12","author":"C Baraldi-Junkins","year":"1993","unstructured":"Baraldi-Junkins C, Levin HR, Kasper EK, et al. Complications of endomyocardial biopsy in heart transplant patients. J Heart Lung Transplant. 1993;12:63\u20137.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1600-6143.2005.00869.x","volume":"5","author":"RW Evans","year":"2005","unstructured":"Evans RW, Williams GE, Baron HM, et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant. 2005;5:1553\u20138.","journal-title":"Am J Transplant"},{"key":"184_CR16","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","volume":"6","author":"JA Kobashigawa","year":"2006","unstructured":"Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377\u201386.","journal-title":"Am J Transplant"},{"key":"184_CR17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","volume":"18","author":"T Mathew","year":"2004","unstructured":"Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies*. Clin Transplant. 2004;18:446\u20139.","journal-title":"Clin Transplant"},{"key":"184_CR18","doi-asserted-by":"crossref","unstructured":"Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. 2006. p. 581\u2013589.","DOI":"10.1681\/ASN.2005090993"},{"key":"184_CR19","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1600-6143.2009.02997.x","volume":"10","author":"R Salgo","year":"2010","unstructured":"Salgo R, Gossmann J, Sch\u00f6fer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385\u201393.","journal-title":"Am J Transplant"},{"key":"184_CR20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0190-9622(99)70185-4","volume":"40","author":"P Jensen","year":"1999","unstructured":"Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177\u201386.","journal-title":"J Am Acad Dermatol"},{"key":"184_CR21","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1056\/NEJMe058018","volume":"352","author":"J Dantal","year":"2005","unstructured":"Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352:1371\u20133.","journal-title":"N Engl J Med"},{"key":"184_CR22","doi-asserted-by":"crossref","unstructured":"Caforio ALP, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients : risk factor analysis and relevance of immunosuppressive therapy. 2000. p. III\u2013222\u2013III\u2013227.","DOI":"10.1161\/01.CIR.102.suppl_3.III-222"},{"key":"184_CR23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","volume":"349","author":"HJ Eisen","year":"2003","unstructured":"Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847\u201358.","journal-title":"N Engl J Med"},{"key":"184_CR24","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","volume":"110","author":"A Keogh","year":"2004","unstructured":"Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2\u00a0years: a randomized clinical trial. Circulation. 2004;110:2694\u2013700.","journal-title":"Circulation"},{"key":"184_CR25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.healun.2005.11.452","volume":"25","author":"JA Kobashigawa","year":"2006","unstructured":"Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25:434\u20139.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","volume":"24","author":"HJ Eisen","year":"2005","unstructured":"Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517\u201325.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR27","doi-asserted-by":"crossref","unstructured":"Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. 2005. p. 2705\u20132713.","DOI":"10.1056\/NEJMoa032953"},{"key":"184_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","volume":"66","author":"AO Gaber","year":"1998","unstructured":"Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66:29\u201337.","journal-title":"Transplantation"},{"key":"184_CR29","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/0735-1097(93)90237-U","volume":"21","author":"JA Kobashigawa","year":"1993","unstructured":"Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol. 1993;21:1142\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"184_CR30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.0000070421.38604.2B","volume":"108","author":"D Mancini","year":"2003","unstructured":"Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108:48\u201353.","journal-title":"Circulation"},{"key":"184_CR31","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0002-9149(96)00427-4","volume":"78","author":"E Arbustini","year":"1996","unstructured":"Arbustini E, Roberts WC. Morphological observations in the epicardial coronary arteries and their surroundings late after cardiac transplantation (allograft vascular disease). Am J Cardiol. 1996;78:814\u201320.","journal-title":"Am J Cardiol"},{"key":"184_CR32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00001573-200403000-00018","volume":"19","author":"MC Fishbein","year":"2004","unstructured":"Fishbein MC, Kobashigawa J. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy. Curr Opin Cardiol. 2004;19:166\u20139.","journal-title":"Curr Opin Cardiol"},{"key":"184_CR33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","volume":"359","author":"AA Vo","year":"2008","unstructured":"Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359:242\u201351.","journal-title":"N Engl J Med"},{"key":"184_CR34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.surge.2010.11.023","volume":"9","author":"JK Patel","year":"2011","unstructured":"Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon. 2011;9:160\u20137.","journal-title":"Surgeon"},{"key":"184_CR35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJM199812103392404","volume":"339","author":"ML Barr","year":"1998","unstructured":"Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998;339:1744\u201351.","journal-title":"N Engl J Med"},{"key":"184_CR36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.healun.2005.10.004","volume":"25","author":"JK Kirklin","year":"2006","unstructured":"Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant. 2006;25:283\u20138.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2008.12.017","volume":"28","author":"J Kobashigawa","year":"2009","unstructured":"Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28:213\u201325. This is a summary of the current state of the-art on the diagnosis and management of sensitized heart transplant candidates based on the consensus of experts in the field.","journal-title":"J Heart Lung Transplant"},{"key":"184_CR38","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.healun.2011.08.009","volume":"30","author":"J Patel","year":"2011","unstructured":"Patel J, Everly M, Chang D, et al. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30:1320\u20136.","journal-title":"J Heart Lung Transplant"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0184-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-012-0184-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-012-0184-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T02:58:49Z","timestamp":1561777129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-012-0184-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1007\/s11936-012-0184-7","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]}}}